Comparative evaluation of preclinical in vivo models for the assessment of replicating retroviral vectors for the treatment of glioblastoma

Journal of Neuro-Oncology

Volumn 102, Issue 1, 2011, Pages 59-69

  Hlavaty, Juraj ^a   Jandl, Gerrit ^a   Liszt, Melissa ^a   Petznek, Helga ^a   König Schuster, Marielle ^a   Sedlak, Jenny ^a   Egerbacher, Monika ^a   Weissenberger, Jakob ^b   Salmons, Brian ^c   Günzburg, Walter H ^a   Renner, Matthias ^a  

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c Austrianova Singapore Pte Ltd   (Singapore)

Author keywords

Gene therapy; Glioblastoma; Glioma; Replication competent retroviral vector; Suicide genes

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; RETROVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BYSTANDER EFFECT; CANCER CELL CULTURE; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; EMBRYO; GENE TRANSFER; GENETIC TRANSFECTION; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LD 50; MOLONEY LEUKEMIA ONCOVIRUS; MOUSE; NONHUMAN; PLASMID; RAT; SUICIDE GENE THERAPY; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

ANIMALS; BRAIN NEOPLASMS; BYSTANDER EFFECT; CYTOSINE DEAMINASE; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FLUCYTOSINE; FLUOROURACIL; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; GLIOBLASTOMA; HUMANS; MICE; MICE, NUDE; MICE, SCID; PRODRUGS; RETROVIRIDAE; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

EID: 79952193873     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0295-5     Document Type: Article

References (40)

1. Miller CR, Perry A (2007) Glioblastoma. Morphologic and molecular genetic diversity. Arch Pathol Lab Med 131(3):397-406
2. Hegi ME, Murat A, Lambiv WL et al (2006) Brain tumors: molecular biology and targeted therapies. Ann Oncol 17(Suppl. 10):x191-x197 (Pubitemid 44542008)
3. Mizuno M, Yoshida J, Colosi P et al (1998) Adeno-associated virus vector containing the herpes simplex virus thymidine kinase gene causes complete regression of intracerebrally implanted human gliomas in mice, in conjunction with ganciclovir administration. Jpn J Cancer Res 89(1):76-80 (Pubitemid 28067514)
4. Tymiryasova TM, Chen B, Haghighat P (1999) Vaccinia virus-mediated expression of wild-type p53 suppresses glioma cell growth and induces apoptosis. Int J Oncol 14(5):845-854
5. Ren H, Boulikas T, Lundstrom K et al (2003) Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki Forest virus vector carrying the human interleukin-12 gene-a phase I/II clinical protocol. J Neurooncol 64(1-2):147-154 (Pubitemid 36992469)
6. Shand N, Weber F, Mariani L et al (1999) A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. Hum Gene Ther 10(14):2325-2335 (Pubitemid 29459843)
7. Rainov NG, Ren H (2003) Clinical trials with retrovirus mediated gene therapy - what we have learned? J Neurooncol 65(3):227-236
8. Smitt PS, Driesse M, Wolbers J et al (2003) Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir. Mol Ther 7(6):851-858 (Pubitemid 36790262)
9. Conrad C, Miller CR, Ji Y, Gomez-Manzano C et al (2005) Δ24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization. Cancer Gene Ther 12(3):284-294 (Pubitemid 40315188)
10. Wollmann G, Tattersall P, van den Pol AN (2005) Targeting human glioblastoma cells: comparison of nine viruses with oncolytic potential. J Virol 79(10):6005-6022 (Pubitemid 40617207)
11. Sonabend AM, Ulasov IV, Han Y et al (2006) Oncolytic adenoviral therapy for glioblastoma multiforme. Neurosurg Focus 20(4):1-10
12. Ulasov IV, Sonabend AM, Nandi S et al (2009) Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptic cell death in vivo. Br J Cancer 100(7):1154-1164
13. Solly SK, Trajcevski S, Frisen C et al (2003) Replicative retroviral vectors for cancer gene therapy. Cancer Gene Ther 10(1):30-39 (Pubitemid 36222074)
14. Dalba C, Bellier B, Kasahara N et al (2007) Replication-competent vectors and empty virus-like particles: new retroviral vector designs for cancer gene therapy or vaccines. Mol Ther 15(3):457-466
15. Tai CK, Kasahara N (2008) Replication-competent retrovirus vectors for cancer gene therapy. Front Biosci 13:3083-3095
16. Wang WJ, Tai CK, Kasahara N et al (2003) Highly efficient and tumor-restricted gene transfer to malignant gliomas by replication-competent retroviral vectors. Hum Gene Ther 14(2):117-127 (Pubitemid 36418816)
17. Wang WJ, Tai CK, Kershaw AD et al (2006) Use of replication-competent retroviral vectors in an immunocompetent intracranial glioma model. Neurosurg Focus 20(4):1-7
18. Tai CK, Wang WJ, Chen TC et al (2005) Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma. Mol Ther 12(5):842-851 (Pubitemid 41614479)
19. Mathieu V, De Neve N, Le Mercier M et al (2008) Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia 10(12):1383-1392
20. Xie Q, Thompson R, Hardy K et al (2008) A highly invasive human glioblastoma pre-clinical model for testing therapeutics. J Transl Med 6:77-85
21. Fomchenko EI, Holland EC (2006) Mouse models of brain tumors and their applications in preclinical trials. Clin Cancer Res 12(18):5288-5297 (Pubitemid 44497241)
22. Smilowitz HM, Weissenberger J, Weis J et al (2007) Orthotopic transplantation of v-src expressing glioma cell lines into immunocompetent mice: establishment of a new transplantable in vivo model for malignant glioma. J Neurosurg 106(4):652-659 (Pubitemid 46536463)
23. Martinez-Murillo R, Martinez A (2007) Standardization of an orthotopic mouse brain tumor model following transplantation of CT-2A astrocytoma cells. Histol Histopathol 22(12):1309-1326 (Pubitemid 47470324)
24. Boyd M, Cunningham SH, Brown MM et al (1999) Noradrenaline transporter gene transfer for radiation cell kill by 131I metaiodobenzylguanidine. Gene Ther 6(6):1147-1152 (Pubitemid 29295221)
25. Perzelova A, Macikova I, Mraz P et al (1998) Characterization of two new permanent glioma cell lines 8-MG-BA and 42-MG-BA. Neoplasma 45(1):25-29 (Pubitemid 28157056)
26. Zimmerman MH (1955) The nature of gliomas as revealed by animal experimentation. Am J Pathol 31:1-29
27. Sundarraj N, Schachner M, Pfeiffer SE (1975) Biochemically differentiated mouse glial lines carrying a nervous system specific cell surface antigen (NS-1). Proc Natl Acad Sci USA 72(5): 1927-1931
28. Ausman JI, Shapiro WR, Rall DP (1970) Studies on the chemotherapy of experimental brain tumors: development of an experimental model. Cancer Res 30(9):2394-2400
29. Weissenberger J, Steinbach JP, Malin G et al (1997) Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice. Oncogene 14(17):2005-2013 (Pubitemid 27237002)
30. Pohl U, Wick W, Weissenberger J et al (1999) Characterization of Tu-2449, a glioma cell line derived from a spontaneous tumor in GFAP-v-src-transgenic mice: comparison with established murine glioma cell lines. Int J Oncol 15(4):829-834
31. Schmidek HH, Nielsen SL, Schiller AL et al (1971) Morphological studies of rat brain tumors induced by N-nitrosomethylurea. J Neurosurg 34(3):335-340
32. Liehl B, Hlavaty J, Moldzio R et al (2007) Simian immunodeficiency virus vector pseudotypes differ in transduction efficiency and target cell specificity in brain. Gene Ther 14(18):1330-1343 (Pubitemid 47365619)
33. Klein D, Indraccolo S, von Rombs K et al (1997) Rapid identification of viable retrovirus-transduced cells using the green fluorescent protein as a marker. Gene Ther 4(8):1256-1260 (Pubitemid 27493889)
34. Hlavaty J, Portsmouth D, Stracke A et al (2004) Effects of sequences of prokaryotic origin on titer and transgene expression in retroviral vectors. Virology 330(1):351-360 (Pubitemid 39446592)
35. Evans LH, Morrison RP, Malik FG et al (1990) A neutralizable epitope common to the envelope glycoproteins of ecotropic, polytropic, xenotropic, and amphotropic murine leukemia viruses. J Virol 64(12):6176-6183
36. Block ER, Bennett JE (1972) Pharmacological studies with 5-fluorocytosine. Antimicrob Agents Chemother 1(6):476-482
37. Slingsby JH, Baban D, Sutton J et al (2000) Analysis of 4070A envelope levels in retroviral preparations and effect on target cell transduction efficiency. Hum Gene Ther 11(10):1439-1451 (Pubitemid 30451024)
38. Vermes A, Guchelaar HJ, Dankert J (2000) Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 46(2): 171-179 (Pubitemid 30639285)
39. Bolteus AJ, Berens ME, Pilkington GJ (2001) Migration and invasion in brain neoplasms. Curr Neurol Neurosci Rep 1(3): 225-232
40. Claes A, Idema AJ, Wesseling P (2007) Diffuse glioma growth: a guerilla war. Acta Neuropathol 114(5):443-458 (Pubitemid 47521501)